How This Pharma Stock Could Knock Eli Lilly Off Its Diabetes Pedestal

How This Pharma Stock Could Knock Eli Lilly Off Its Diabetes Pedestal

Source: 
Investors Business Daily
snippet: 

Novo Nordisk stock popped Tuesday after an analyst suggested the pharmaceutical company's oral diabetes treatment could swipe share from Eli Lilly's (LLY) rival drug, Trulicity.